Expanded haploidentical NK cells

Phase 2Cell therapy

HHospital Infantil Universitario Niño Jesús, Madrid, Spain

Expanded haploidentical NK cells is one of 4 biologic programs targeting Natural Killer Cell. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Natural Killer CellRecruiting

Natural Killer CellPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Natural Killer Cell

#DrugCompanyPhaseTrials

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 2

NK Cells

SSouthwest Hospital, China

Phase 1

1 3

NKX019

NNkarta, Inc.

Phase 1

1 4

Expanded haploidentical NK cells

HHospital Infantil Universitario Niño Jesús, Madrid, Spain

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leukemia1 trial

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

Completed·—·Phase 1·NCT04327037·10 enrolled

Lymphoma1 trial

Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma

Terminated·HHospital Infantil Universitario Niño Jesús, Madrid, Spain·Phase 1/2·NCT01944982·7 enrolled

Natural Killer Cell1 trial

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Recruiting·—·Phase 1/2·NCT05334693·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Expanded haploidentical NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Expanded haploidentical NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Expanded haploidentical NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Infantil Universitario Niño Jesús, Madrid, Spain company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: HHospital Infantil Universitario Niño Jesús, Madrid, Spain

Expanded haploidentical NK cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leukemia1 trial

Lymphoma1 trial

Natural Killer Cell1 trial

References

Drug Info

Quick Facts

Related News